SCHEMBL9971307

SCHEMBL9971307

COc1ccc(C(c2ccccc2)(c2ccc(OC)cc2)N2C(=O)NC3C(CCCC(=O)NCCCCCO)SCC32)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.40
SENP1 Q9P0U3 1/20 0.38
TDP1 Q9NUW8 1/20 0.36
HSP90AB1 P08238 1/20 0.36
ALDH1A1 P00352 3/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
ITGB1 P05556 1/20 0.36
ITGA4 P13612 1/20 0.36
HSPA8 P11142 2/20 0.36
GIGYF2 Q6Y7W6 1/20 0.35
HDAC3 O15379 1/20 0.35
HDAC1 Q13547 1/20 0.35
NAMPT P43490 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16141184 0.89 HLCS (0.39) KEAP1TDP1ALDH1A1SMN1; SMN2
SCHEMBL30929049 0.88 HSP90AB1 (0.43) KEAP1HSP90AB1
SCHEMBL30929050 0.88 HSP90AB1 (0.43) KEAP1HSP90AB1
SCHEMBL30205084 0.88 KEAP1 (0.40) KEAP1SENP1TDP1HSP90AB1ALDH1A1
SCHEMBL15445418 0.84 KEAP1 (0.37) KEAP1SENP1TDP1HSP90AB1ITGB1
SCHEMBL23812201 0.83 TDP1 (0.47) KEAP1TDP1ALDH1A1
SCHEMBL16478559 0.83 TDP1 (0.47) KEAP1TDP1ALDH1A1
SCHEMBL21606765 0.83 TDP1 (0.42) KEAP1TDP1ALDH1A1
SCHEMBL30205123 0.83 TDP1 (0.42) KEAP1TDP1ALDH1A1
SCHEMBL30331593 0.83 TDP1 (0.42) KEAP1TDP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11773219-B2 Functionalized polymers QUIAPEG PHARMACEUTICALS AB (SE) 2023-10-03 US disclosed
US-20230285574-A1 CONJUGATES OF BIOLOGICALLY ACTIVE MOLECULES TO FUNCTIONALIZED POLYMERS FISH & RICHARDSON PC 2023-09-14 US disclosed
US-11723981-B2 Conjugates of tumor necrosis factor inhibitors to functionalized polymers QUIAPEG PHARMACEUTICALS AB (SE) 2023-08-15 US disclosed
US-9849187-B2 Conjugates of tumor necrosis factor inhibitors to functionalized polymers QUIAPEG PHARMACEUTICALS AB (SE) 2017-12-26 US disclosed
US-9790324-B2 Functionalized polymers QUIAPEG AB 2017-10-17 US disclosed
US-20160354477-A1 CONJUGATES OF TUMOR NECROSIS FACTOR INHIBITORS TO FUNCTIONALIZED POLYMERS FISH & RICHARDSON PC 2016-12-08 US disclosed
US-20160354477-A1 CONJUGATES OF TUMOR NECROSIS FACTOR INHIBITORS TO FUNCTIONALIZED POLYMERS FISH & RICHARDSON PC 2016-12-08 US disclosed
US-9220789-B2 Conjugates of tumor necrosis factor inhibitors to functionalized polymers QUIAPEG PHARMACEUTICALS AB (SE) 2015-12-29 US disclosed
US-9220789-B2 Conjugates of tumor necrosis factor inhibitors to functionalized polymers QUIAPEG PHARMACEUTICALS AB (SE) 2015-12-29 US disclosed
US-20150232615-A1 Functionalized Polymers QUIAPEG AB (SE) 2015-08-20 US disclosed
US-20150232615-A1 Functionalized Polymers QUIAPEG AB (SE) 2015-08-20 US disclosed
US-20150147345-A1 CONJUGATES OF BIOLOGICALLY ACTIVE MOLECULES TO FUNCTIONALIZED POLYMERS QUIAPEG AB (SE) 2015-05-28 US disclosed
US-20150147345-A1 CONJUGATES OF BIOLOGICALLY ACTIVE MOLECULES TO FUNCTIONALIZED POLYMERS QUIAPEG AB (SE) 2015-05-28 US disclosed
US-20140030278-A1 CONJUGATES OF TUMOR NECROSIS FACTOR INHIBITORS TO FUNCTIONALIZED POLYMERS QUIAPEG AB (SE) 2014-01-30 US disclosed
US-20140030278-A1 CONJUGATES OF TUMOR NECROSIS FACTOR INHIBITORS TO FUNCTIONALIZED POLYMERS QUIAPEG AB (SE) 2014-01-30 US disclosed
WO-2012080836-A2 FUNCTIONALIZED POLYMERS KWIATKOWSKI MAREK (SE) 2012-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230285574-A1 CONJUGATES OF BIOLOGICALLY ACTIVE MOLECULES TO FUNCTIONALIZED POLYMERS CD44, EPCAM, ALG1 KEAP1 4080/4885SENP1 1472/4885TDP1 1794/4885
US-20150147345-A1 CONJUGATES OF BIOLOGICALLY ACTIVE MOLECULES TO FUNCTIONALIZED POLYMERS CD44, EPCAM, ALG1 KEAP1 4080/4885SENP1 1472/4885TDP1 1794/4885
US-11723981-B2 Conjugates of tumor necrosis factor inhibitors to functionalized polymers TNF, TNFRSF1A, TNFSF11 KEAP1 3499/4885SENP1 598/4885TDP1 2625/4885
US-11773219-B2 Functionalized polymers PARG, PUF60, PCBP1 KEAP1 4387/4885SENP1 2525/4885TDP1 1616/4885
US-20160354477-A1 CONJUGATES OF TUMOR NECROSIS FACTOR INHIBITORS TO FUNCTIONALIZED POLYMERS TNF, TNFRSF1A, TNFSF11 KEAP1 3499/4885SENP1 598/4885TDP1 2625/4885
US-20140030278-A1 CONJUGATES OF TUMOR NECROSIS FACTOR INHIBITORS TO FUNCTIONALIZED POLYMERS TNF, TNFRSF1A, TNFSF11 KEAP1 3499/4885SENP1 598/4885TDP1 2625/4885
US-20150232615-A1 Functionalized Polymers PARG, PUF60, PCBP1 KEAP1 4387/4885SENP1 2525/4885TDP1 1616/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.